Top-Tipp $$$$$$$$$$ Heute noch 100%$$$$$ - 500 Beiträge pro Seite

[mayday18]

Roche zahlt Meilensteine für weitere Entwicklungen von Maxygen WKN:931314 in Frankfurt, Berlin-Bremen, Nasdaq.

Roche zahlt 230 Miliionen Dollar über zwei Jahre plus Vertriebskosten und Produktionskosten. Maxygen, Kürzel MAXY
schloß gestern bei 8,11 Dollar an der Nasdaq. Die Nachricht kam nach Börsenschluß. Für heute ist um 4.30 PM eine Telefonkonferenz geplant.

Maxygen hat bisher Antiviren z.B. für Hepattitis B und HIV entwickelt. Im letzten Quartalsbericht konnten deutliche Ergenisverbesserungen berichtet werden. Die Schulden betragen insgesamt ca. 140 Mio. Dollar. Nach meiner Auffassung eine Riesenchance jetzt noch schnell in Deutschland einzusteigen, bevor der Kurs in Amerika explodiert. gehe locker von 100% aus!


Infos unter vwd.de Bericht: Roche zahlt 230 Millionen.....
und unter www.wallstreetcity.com Kürzel MAXY

Viel Glück!

[mayday18]

Leute kauft! Ist aber schwierig irgendwo Stücke zu bekommen.

[kaiser23]

Sorry aber du bist zu langsam die schnellen und guten trader haben schon gestern gekauft,grins schade aber vieleicht beim nächsten mal......

[mayday18]

Hallo Kaiser23

Die Meldung kam gestern erst weit nach Börsenschluß. In Deutschland gestern 700 Euro Umsatz. In amiland 160.000 Stücke zwischen 8,00 und 8,05 alles in der normalen Handelszeit. Schau Dir mal die Bid/Ask Stellung in Amerika an? Fällt Dir dann etwas auf?

Hier nochmal der Bericht (Die Telefonkonferenz findet ineresaanterweise heute erst nach Börsenschluß um 4:30 PM statt)

Roche and Maxygen Establish Broad Alliance to Develop and CommercializeNext-Generation Interferon Alpha and Beta Products

BASEL, Switzerland and REDWOOD CITY, Calif., May 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- -- Roche and Maxygen, Inc. (Nasdaq: MAXY) announced today that they have formed a broad strategic alliance to collaborate on the global development and commercialization of Maxygen`s portfolio of next-generation interferon alpha and beta variants for a wide range of indications.

The collaboration will initially focus on the development of lead candidates for hepatitis B virus (HBV) and hepatitis C virus (HCV) that have been designed by Maxygen to have novel and superior efficacy compared to currently marketed interferon alpha products. This builds on Roche`s commitment to hepatitis, following Pegasys, a new generation interferon that provides significant benefit over conventional interferon therapy in patients infected with HCV.

Terms of the Agreement

Roche has licensed worldwide commercialization rights to specific novel interferon product candidates for HBV and HCV. Maxygen will receive an initial payment, full research and development funding for the first two years of the collaboration and option fees. In addition, Maxygen is eligible to receive milestone payments and royalties based on product sales.

The agreement also provides the companies with the option to expand the collaboration to develop other novel interferon alpha and beta products specifically tailored for indications outside of HBV and HCV, including oncology, autoimmune diseases, inflammatory diseases, and other infectious diseases such as HIV. Maxygen retains the right to develop such products while Roche may elect to acquire worldwide license and commercialization rights to these product candidates.

Maxygen has the option to co-develop in the United States any product to which Roche acquires a license in exchange for profit sharing or an increased royalty rate.

Based on the continued successful development of the novel interferon product candidates and the satisfaction of certain contingencies, payments to Maxygen could exceed $230 million plus royalties on product sales.

"Roche has a long tradition in successfully developing and commercializing anti-viral drugs, alone or in partnership with other companies. We believe with Pegasys and Copegus we are establishing a new standard of care. Maxygen`s portfolio of lead interferon product candidates represents an interesting and novel approach for further improvement in treatment. We are convinced that through our collaboration we will continue to be a clear leader in the treatment of patients suffering from this debilitating disease," said William M. Burns, Head of Roche`s Pharmaceuticals Division.

"Maxygen`s strategy has always been to partner with world leaders in their respective fields, and with its track record of excellence and an established and strong franchise, Roche is clearly a leader in the development and commercialization of interferon therapies," said Russell Howard, Ph.D., Chief Executive Officer of Maxygen. "This innovative collaboration is structured to maximize the commercial potential of Maxygen`s novel shuffled interferons by enabling their swift development and potential commercialization with a market leader in hepatitis. Importantly, Maxygen retains the right to conduct further discovery and development of novel interferons for additional indications. I am particularly excited about Maxygen`s option to co-develop these products for hepatitis B and C in the U.S., as this provides substantial potential for long-term value creation for the company."

The Interferon Alpha Market

Total global interferon alpha sales (including ribavirin) for all indications including hepatitis B, C and several cancers were in excess of $2.9 billion in 2002.

About Hepatitis B

Hepatitis B is a blood-born virus that attacks the liver and is the most common serious liver infection in the world. The HBV virus is highly contagious and is relatively easy to transmit from one infected individual to another. It is 100 times more infectious than the HIV virus.

About Hepatitis C

Hepatitis C is a serious blood-born viral infection that attacks the liver, and in many patients it leads to liver disease, cirrhosis and cancer. It is the leading cause of liver transplantation. Only identified in 1989, the HCV virus has infected more than 170 million people world-wide, making it more common than the HIV virus.

Roche`s Commitment to Hepatitis

Roche is committed to the viral hepatitis disease area, having introduced Roferon-A for hepatitis B and then C, followed by Pegasys and Copegus in hepatitis C. Pegasys is a new generation hepatitis C therapy that is different by design and provides significant benefit over conventional interferon therapy in patients infected with HCV of all genotypes. The benefits of Pegasys are derived from its new generation large 40 kilodalton branched-chain polyethylene glycol (PEG) construction, which allows for constant viral suppression. Pegasys is approved for monotherapy and for use in combination with Copegus, our proprietary ribavirin product in more than 70 countries, including the European Union and the United States. The most recent approvals for Pegasys have occurred in China and New Zealand. Pegasys is also in phase III clinical development for patients infected with the HBV virus. Roche manufactures and sells the AMPLICOR(TM) HCV Test, v2.0 and the AMPLICOR HCV MONITOR(TM) Test, v2.0 -- two tests used to detect the presence of HCV RNA (Ribo Nucleic Acid) in a person`s blood. Roche`s commitment to hepatitis has been further reinforced by the in-licensing of Levovirin, which will be studied with the objective of demonstrating superior tolerability over the current standard, ribavirin.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world`s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people`s health and quality of life. Roche employs roughly 62,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.

About Maxygen

Maxygen, Inc. headquartered in Redwood City, California, is focused on creating novel products using its integrated proprietary technologies for human therapeutics and industrial applications. Maxygen`s technologies bring together advances in molecular biology and protein modification to create novel biotechnology products. Maxygen has strategic collaborations with leading pharmaceutical companies including Roche, Aventis, InterMune, Lundbeck, ALK-Abello, and the International AIDS Vaccine Initiative (IAVI). Additionally, Maxygen has a range of other strategic alliances in industrial applications, as well as funding from U.S.A. government organizations including USAID, US Army Medical Research and Materiel Command and NIST-ATP.

Conditions

The transaction is being submitted for review by the Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Webcast

Maxygen will host a conference call at 1:30PM PDT / 4:30PM EDT on Thursday, May 22, 2003 to discuss this announcement. The live webcast may be accessed by visiting the Investor Information section of the Company`s website, www.maxygen.com. Following the webcast, an archived version of the call will be available at the same address until June 22, 2003.

Maxygen Forward-looking Statements

This news release contains forward-looking statements about Maxygen`s research and business prospects, including those relating to: Maxygen`s ability to develop and commercialize next-generation interferons, their attributes and indications; the speed of such development and the potential payments Maxygen will receive from the collaboration. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Among other things these risks and uncertainties include, but are not limited to: the inability to develop viable commercial product candidates; changing research and business priorities of Maxygen and Roche; competitors producing superior products and the inherent uncertainties of biological and clinical research. These and other risk factors are more fully discussed in Maxygen`s Form 10-K for the year ended December 31, 2002, including under the caption "Risk Factors," and in Maxygen`s other periodic SEC reports, all of which are available from Maxygen at www.maxygen.com. Maxygen disclaims any obligation to update or revise any forward-looking statement contained in this release as a result of new information or future events or developments. Maxygen and the Maxygen logo are registered trademarks of Maxygen.

NOTE: All trademarks used or mentioned in this release are legally protected.

SOURCE Maxygen, Inc.


CONTACT: Alison Trollope, Investor & Public Relations of Maxygen, Inc.,
[phone], or fax, [phone]; or Roche Corporate Communications
Centre, +011-41-61-688-88-88, or fax, +011-41-61-688-27-75

[mayday18]

Tippe mal auf eine Eröffnung in Amiland bei 17-20. Schlu0kurs 24.

Wir werden sehen!

[mayday18]

Auszug aus dem Q1-Bericht:

We have incurred net losses since our inception, including a net loss of approximately $45.0 million in 2001, $33.9 million in 2002 and $4.3 million in the three months ended March 31, 2003. As of March 31, 2003, we had an accumulated deficit of approximately $166.6 million. We expect to have net losses and negative cash flow for at least the next several years.


das haben die vor ein paar Tagen gemeldet. Übrigens wurde die Finanzierung bis dato u.a. von der Regierung abgesichert.

Und heute die Meldung über den 230 Mio. Dollar Deal mit Roche (auch nicht gerade ein unbekanntes Unternehmen, daß Risikoinvestitionen in No-Name - Firmen vornimmt)

Die 230 Mio. Dollar sind durch die Übernahme der Sales und
Produktkosten für die Weterentwicklung quasi als Nettozufluß zu betrachten. Damit wird die Company erstmals immense Erträge erwirtschaften.

Aber noch scheint es fast niemanden zu interessieren. Freue mich auf die Börseneröffnung in Amerika.

[ohshit]

Hast Du schon Aktien von MAXY oder kaufst Du erst heute In USA? Was für ein Limit setzt Du Dir? Wie werden die heute eröffnen?

[mayday18]

habe mir welche in Deutschland geholt. Empfehle Dir aber USA. Kurs im Moment vorbörslich bei 9,56. Ist aber sicher erst der Anfang.

[mayday18]

geht langsam aufwärts. 10,37 tendenz steigend.

[ohshit]

Der Kursanstieg in USA entspricht zur Zeit genau dem in D (+28%). Aber zu Höchstkursen gehe ich sicher nicht rein. Solche Werte handelt man wirklich besser an der Heimatbörse.

[ohshit]

Irgendwie habe ich das Gefühl, das wird nix mit den 100% heute. Schon wieder unter 10$